Skip to main content
SpringerLink
Log in

Anticorps anti-HER2

  • Chapter
Les thérapies ciblées

Part of the book series: Oncologie pratique ((ONCOLPRAT))

  • 397 Accesses

Abstrait

Le trastuzumab (Herceptin®), premier traitement par anticorps monoclonal humanisé ciblant un oncogène représente une vraie révolution concernant la prise en charge et ľhistoire naturelle du cancer du sein surexprimant HER2. Ľeffet est notamment spectaculaire en situation adjuvante où il permet dans cinq essais randomisés avec un recul médian de 3 à 4 ans ďéviter une rechute métastatique sur deux et un décès sur trois. Ses indications sont strictement réservées aux cancers du sein présentant une amplification ďHER2 prouvée par FISH ou une forte surexpression (3+) en immunohistochimie. Une surveillance étroite de la fonction ventriculaire gauche durant le traitement est nécessaire afin de détecter et de traiter une éventuelle cardiotoxicité. Le pertuzumab, autre anticorps monoclonal humanisé (2C4), premier inhibiteur de la classe des «antidimérisation», est encore à des stades précoces de développement clinique.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Beuzeboc P, Scholl S, Sastre-Garau X, et al. (1999) Anticorps humanisé anti-HER2 (trastuzumab ou Herceptin®): une avancée thérapeutique majeure dans les cancers du sein exprimant cet oncogène. Bull cancer 86: 544–8

    PubMed  CAS  Google Scholar 

  2. Cornez N, Piccart M (2000) Cancer du sein et Herceptin. Bull Cancer 87: 847–58

    PubMed  CAS  Google Scholar 

  3. Leyland-Jones B (2002) Trastuzumab: hopes and realities. Lancet Oncol 3: 137–44

    Article  PubMed  CAS  Google Scholar 

  4. Schechter AC, Stern BF, Vaidyanathan L, et al. (1984) The neu oncogene: an erbB-related gene encoding a 185 000-Mr tumor antigen. Nature 312: 513–6

    Article  PubMed  CAS  Google Scholar 

  5. Hung MC, Lau YK (1999) Basic science of HER2/neu: a review. Seminars Oncology, 26: 51–9

    CAS  Google Scholar 

  6. Slamon DJ, Clark GM, Wrong SG, et al. (1987) Human breast cancer, correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–82

    Article  PubMed  CAS  Google Scholar 

  7. Mitchell MS, Press MF (1999) The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognostic of breast cancer. Sem Oncol 26: 108–16

    CAS  Google Scholar 

  8. Revillion F, Bonneterre J, Peyrat JP (1998) ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34: 791–808

    Article  PubMed  CAS  Google Scholar 

  9. Ross JS, Fletcher JA (1998) The HER2/neu oncogene in breast cancer: prognostic factor, predictive factor and target for therapy. The oncologist 3: 237–52

    PubMed  Google Scholar 

  10. Trock BJ, Yamauchi H, Brotzman M, et al. (2000) C-erbB2 as a prognostic factor in breast cancer: a meta-analysis. Proc ASCO 19; abstract 372

    Google Scholar 

  11. Press MF, Berstein L, Thomas PA, et al. (1997) HER/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894–904

    PubMed  CAS  Google Scholar 

  12. Kallioniemi OP, Holli K, Visakorpi T, et al. (1991) Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49: 650–5

    Article  PubMed  CAS  Google Scholar 

  13. Carlomagno C, Perrone F, Gallo C, et al. (1996) C-erbB2 over-expression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary-lymph node metastases. J Clin Oncol 14: 2702–8

    PubMed  CAS  Google Scholar 

  14. Elledge RM, Green S, Ciocca D, et al. (1998) HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a southwest oncology group study. Clin Cancer Res 4: 7–12

    PubMed  CAS  Google Scholar 

  15. Houston SJ, Love SB, Wright C, et al. (1999) C-erbB2 protein over-expression in breast cancer is an independant marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79: 1220–6

    Article  PubMed  CAS  Google Scholar 

  16. Stal O, Sullivan S, Wingren S, et al. (1995) C-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31 A: 2185–90

    Article  Google Scholar 

  17. Muss HB, Thor AD, Berry DA, et al. (1994) C-erbB2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260–6

    Article  PubMed  CAS  Google Scholar 

  18. Nieto Y, Cagnoni PJ, Nawaz S, et al. (2000) Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 18: 2070–80

    PubMed  CAS  Google Scholar 

  19. Paik S, Bryant J, Park C, et al. (1998) ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90: 1361–70

    Article  PubMed  CAS  Google Scholar 

  20. Thor AD, Berry DA, Budman DR, et al. (1998) ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90: 1346–60

    Article  PubMed  CAS  Google Scholar 

  21. Pritchard KI, Shepherd LE, O’Malley FP, et al. (2006) National Cancer Institute of Canada Clinical Trials Group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354: 2103–11

    Article  PubMed  CAS  Google Scholar 

  22. Slamon D, Leyland-Jones B, Shak S, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–92

    Article  PubMed  CAS  Google Scholar 

  23. Vincent-Salomon A, Carton M, Freneaux P (2000) ERBB2 expression in breast carcinomas: no correlation with pathological response to high dose anthracycline-based chemotherapy. Eur J Cancer 36: 586–91

    Article  PubMed  CAS  Google Scholar 

  24. von Minckwittz G, Kuemmel S, du Bois A, et al. (2006) Individualized tretment strategies according to in vivo-chemosensitivity assessed by response after 2 cycles of neoadjuvant chemotherapy. Final results of the Gepartrio study of German breast group. Breast Cancer Res Treat S18: Abstr 42

    Google Scholar 

  25. Pegram MD, Finn RS, Arzoo K, et al. (1997) The effect of c-erbB2 Her-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15: 537–47

    Article  PubMed  CAS  Google Scholar 

  26. Jones SE, Savin MA, Holmes FA, et al. (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24: 5381–87

    Article  PubMed  CAS  Google Scholar 

  27. Cobleigh MA, Vogel CL, Tripathy D, et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressd after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–48

    PubMed  CAS  Google Scholar 

  28. Slamon D, Leyland-Jones B, Shak S, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–92

    Article  PubMed  CAS  Google Scholar 

  29. Vogel C, Cobleigh M, Tripathy D, et al. (2002) Efficacy and safety of trastuzumab (Herceptin) as single agent in first-line treatment of HER2 overexpressing metastatic breast cancer. J Clin Oncol 20: 719–26

    Article  PubMed  CAS  Google Scholar 

  30. Vincent-Salomon A, MacGrogan G, et al. (2003) Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology 42: 337–47

    Article  PubMed  CAS  Google Scholar 

  31. Wolff AC, Hammond ME, Schwartz JN, et al. (2007) American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118–45

    Article  PubMed  CAS  Google Scholar 

  32. Couturier J, Nicolas A, Beuzeboc P, et al. (1999) High correlation between ERBB2 amplification detected by FISH and gene overexpression detected by immuno-chemistry in breast cancers. Modern Pathology 12: 18A

    Google Scholar 

  33. Press MF, Slamon DJ, Flam KJ, et al. (2002) Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20: 3095–105

    PubMed  CAS  Google Scholar 

  34. Lal P, Salazar PA, Hudis CA, et al. (2004) HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 121: 631–6

    Article  PubMed  Google Scholar 

  35. Vincent-Salomon A, Jouve M, Genin M, et al. (2002) HER2 status in patients with breast carcinomas is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 94: 2169–73

    Article  PubMed  CAS  Google Scholar 

  36. Seidman A, Hudis C, Pierri MK, et al. (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215–21

    Article  PubMed  CAS  Google Scholar 

  37. Crone AS, Zhao YY, Fan I, et al. (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Med 8: 459–65

    Article  PubMed  CAS  Google Scholar 

  38. Ewer MS, Vooletich MT, Durand JB, et al. (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23: 7820–6

    Article  PubMed  CAS  Google Scholar 

  39. Cook-Bruns N (2001) Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 61: 58–66. Review

    Article  PubMed  CAS  Google Scholar 

  40. Baselga J, Carbonell X, Castaneda NJ, et al. (2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23: 2162–71

    Article  PubMed  CAS  Google Scholar 

  41. Pegram MD, Konecny GE, O’Callaaghan C, et al. (2004) Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96: 739–49

    Article  PubMed  CAS  Google Scholar 

  42. Dieras V, Beuzeboc P, Laurence V, et al. (2001) Interaction between Herceptin and Taxanes. Oncology 61: 43–9

    Article  PubMed  Google Scholar 

  43. Chan A, Martin M, Untch M, et al. (2006) Navelbine Herceptin Project. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer 95: 788–93

    Article  PubMed  CAS  Google Scholar 

  44. Seidman AD, Fornier MN, Esteva FJ, et al. (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587–95

    PubMed  CAS  Google Scholar 

  45. Esteva F, Valero V, Booser D, et al. (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800–8

    Article  PubMed  CAS  Google Scholar 

  46. Burstein HJ, Harris LN, Gelman R, et al. (2003) Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 21: 46–53

    Article  PubMed  CAS  Google Scholar 

  47. Bartsch R, Wenzel C, Pluschnig U, et al. (2006) Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial. Cancer Chemother Pharmacol 7: 554–8

    Article  CAS  Google Scholar 

  48. Stemmler HJ, Kahlert S, Brudler O, et al. (2005) High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study. Clin Oncol 17: 630–5

    Article  CAS  Google Scholar 

  49. Xu L, Song S, Luo R, et al. (2006) Capecitabine+trastuzumab as first-line treatment in patients with HER-2positive metastatic breast cancer: phase II trial results. Breast Cancer Res Treat S102: 2065

    Google Scholar 

  50. Untch M, Himsl I, Kahlert S, et al. (2004) Anthracycline and trastuzumab in breast cancer treatment. Oncology (Williston Park) 18: 59–64

    CAS  Google Scholar 

  51. Wenzel C, Hussian D, Bartsch R, et al. (2004) Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J Cancer Res Clin Oncol 130: 400–4

    Article  PubMed  CAS  Google Scholar 

  52. Lai R, et al. (2004) The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 10: 810–6

    Article  CAS  Google Scholar 

  53. Stemmler HJ, Kahlert S, Siekiera W, et al. (2006) Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15: 219–25

    Article  PubMed  CAS  Google Scholar 

  54. Burstein HJ, Lieberman G, Slamon DJ, et al. (2005) Isolated central nervous system metastases in patients with first-line trastuzumab-based therapy. Ann Oncol 16: 1772–77

    Article  PubMed  CAS  Google Scholar 

  55. Romond EH, Perez EA, Bryant J, et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673–84

    Article  PubMed  CAS  Google Scholar 

  56. Slamon D, Eiermann W, Robert N, et al. (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. 28th Annual San Antonio Breast Cancer Symposium. San Antonio, Abstr 1

    Google Scholar 

  57. Piccart-Gebhart M PM, Leyland-Jones B, et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659–72

    Article  PubMed  CAS  Google Scholar 

  58. Joensuu H, Kellkumpu-Lehtinen PL, Bono P, et al. (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354: 809–20

    Article  PubMed  CAS  Google Scholar 

  59. Smith I, Procter M, Gelber RD, et al. (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer:a randomized controlled trial. Lancet 369: 29–36

    Article  PubMed  CAS  Google Scholar 

  60. Burstein HJ, Harris LN, Gelman R, et al. (2003) Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 21: 46–53

    Article  PubMed  CAS  Google Scholar 

  61. Buzdar AU, Ibrahim NK, Francis D, et al. (2005) Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer. J Clin Oncol 23: 3676–85

    Article  PubMed  CAS  Google Scholar 

  62. Buzdar AU, Valero V, Ibrahim NK, et al. (2007) Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-posotive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13: 228–33

    Article  PubMed  CAS  Google Scholar 

  63. Spector NL, Xia W, Burris H 3rd, et al. (2005) Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23: 2502–12

    Article  PubMed  CAS  Google Scholar 

  64. Burris HA 3rd, Hurwitz HI, Dees ED, et al. (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23: 5305–13

    Article  PubMed  CAS  Google Scholar 

  65. Albanell J, Baselga J (2001) Unraveling resistance to trastuzumab (Herceptin): Insulin-like growth factor-I receptor, a new suspect. J Natl Cancer Inst 93: 1830–32

    Article  PubMed  CAS  Google Scholar 

  66. Lu Y, Zi X, Zhao Y, et al. (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852–7

    Article  PubMed  CAS  Google Scholar 

  67. Nagata Y, Lan KH, Zhou X, et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117–27

    Article  PubMed  CAS  Google Scholar 

  68. Kim C, Bryant J, Horne Z, et al. (2005) Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. SABCS, Abstr 46

    Google Scholar 

  69. Tagliabue E, Agresti R, Carcangiu ML, et al. (2003) Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 362: 527–33

    Article  PubMed  CAS  Google Scholar 

  70. Marty M, Cognetti F, Maraninchi D, et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group, J Clin Oncol 23: 4265–74

    Article  PubMed  CAS  Google Scholar 

  71. Fountzilas G, Razis E, Tsavdaridis D, et al. (2003) Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer 4: 120–5

    Article  PubMed  CAS  Google Scholar 

  72. Geyer CE, Forster J, Lindquist D, et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 28: 2733–43

    Article  Google Scholar 

  73. Pegram M, Chan, Dichmann RA, et al. (2006) Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab and bevacizumab as first line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat S28: 301

    Google Scholar 

  74. Buron C, Doz M, Vincent-Salomon A, et al. (2007) Facteurs favorisant la diffusion de ľinnovation en santé, ľexemple ďHerceptin. Bull Cancer 94: 297–306

    PubMed  Google Scholar 

  75. Liberato NL, Marchetti M, Barosi G (2007) Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 25: 625–33

    Article  PubMed  Google Scholar 

  76. Kurian AW, Thompson RN, Gaw AF, et al. (2007) A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol 25: 634–41

    Article  PubMed  CAS  Google Scholar 

  77. de Pinieux G, Colin D, Vincent-Salomon A, et al. (2004) Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/neu (c-erbb-2) status in urothelial carcinoma. Virchows Arch 444: 415–9

    Article  PubMed  Google Scholar 

  78. Agus DB, Gordon MS, Taylor C, et al. (2005) Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23: 2534–43

    Article  PubMed  CAS  Google Scholar 

  79. Gordon MS, Matei D, Aghajanian C, et al. (2006) Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24: 4324–32

    Article  PubMed  CAS  Google Scholar 

  80. De Bono JS, Bellmunt J, Attard G, et al. (2007) Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 25: 257–62

    Article  PubMed  CAS  Google Scholar 

  81. Walshe JM, Denduluri N, Berman AW, et al. (2006) A phase II trial with trastuzumab and pertuzumab in patients with HER-2 over expressed locally advanced and metastatic breast cancer. Clin Breast Cancer 6: 535–9

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Département ďoncologie médicale, Institut Curie, 26, rue ďUlm, 75005, Paris

    P. Beuzeboc & S. Scholl

  2. Service ďoncologie médicale, Hôpital Tenon, 4, rue de Chine, 75020, Paris

    J. Gligorov

Authors
  1. P. Beuzeboc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Scholl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Gligorov
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag France

About this chapter

Cite this chapter

Beuzeboc, P., Scholl, S., Gligorov, J. (2008). Anticorps anti-HER2. In: Les thérapies ciblées. Oncologie pratique. Springer, Paris. https://doi.org/10.1007/978-2-287-36008-4_1

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-36008-4_1

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-36007-7

  • Online ISBN: 978-2-287-36008-4

Publish with us

Policies and ethics

Search

Navigation